Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32688366 | 0.89 | ACMSD (0.47) | MEN1POLBKMT2AADORA1ADORA2A | |
| SCHEMBL32688043 | 0.88 | LMNA (0.45) | MEN1POLBKMT2ACXCR2HSD11B1 | |
| SCHEMBL32687967 | 0.87 | MEN1 (0.43) | MEN1POLBKMT2ACXCR2HSD11B1 | |
| SCHEMBL32688294 | 0.84 | MEN1 (0.41) | MEN1POLBKMT2AHSD11B1 | |
| SCHEMBL32688267 | 0.84 | ADORA1 (0.40) | MEN1POLBKMT2AADORA1ADORA2A | |
| SCHEMBL32688407 | 0.84 | ACMSD (0.39) | MEN1POLBKMT2AADORA1ADORA2A | |
| SCHEMBL32688268 | 0.83 | MEN1 (0.42) | MEN1POLBKMT2AADORA1ADORA2A | |
| SCHEMBL32688228 | 0.82 | HSD11B1 (0.40) | MEN1POLBKMT2AADORA1ADORA2A | |
| SCHEMBL32688144 | 0.80 | MEN1 (0.48) | MEN1POLBKMT2AADORA1ADORA2A | |
| SCHEMBL32688285 | 0.80 | POLB (0.40) | MEN1POLBKMT2AADORA1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078105-A1 | Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors | ORSOBIO INC (US) | 2026-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078105-A1 | Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors | CPT1B, CBR1, MUSK | MEN1 4353/4885POLB 508/4885KMT2A 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.